Arbutus Biopharma Corporation
ABUS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $871 | $592 | $666 | $607 |
| - Cash | $22 | $37 | $37 | $36 |
| + Debt | $1 | $5 | $1 | $1 |
| Enterprise Value | $849 | $559 | $630 | $572 |
| Revenue | $1 | $11 | $2 | $2 |
| % Growth | -95.1% | 508.8% | 12.1% | – |
| Gross Profit | $1 | $11 | -$7 | -$7 |
| % Margin | 97.9% | 100% | -407.9% | -459.7% |
| EBITDA | -$8 | $3 | -$24 | -$15 |
| % Margin | -1,457.1% | 23.9% | -1,369.9% | -974.3% |
| Net Income | -$8 | $3 | -$25 | -$13 |
| % Margin | -1,463.5% | 23.5% | -1,390.4% | -796.2% |
| EPS Diluted | -0.04 | 0.013 | -0.13 | -0.068 |
| % Growth | -405.3% | 110.1% | -92.6% | – |
| Operating Cash Flow | -$6 | -$16 | -$13 | -$10 |
| Capital Expenditures | $0 | $0 | $0 | -$0 |
| Free Cash Flow | -$6 | -$16 | -$13 | -$10 |